FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting.The designation recognizes the program ...

Telix Pharmaceuticals (ASX:TLX) has secured FDA Fast Track for its BiPASS program, opening the pre-biopsy prostate cancer ...

PSA is a prostate test, not a cancer test. Any breakdown in the cells of the prostate can make it leak. A raised result could ...

UCLA investigators present the latest radiotherapy research at the American Society for Radiation Oncology annual meeting ...

Robert Uzzo, MD, MBA, of Fox Chase Cancer Center discusses an evolution in prostate cancer screening modalities.

Medvue Concorde medical imaging clinic has become the first in Quebec to acquire the Siemens MAGNETOM Flow.Elite, a next-generation magnetic resonance imaging (MRI) system that integrates artificial ...

A prostate biopsy can tell doctors whether cancer is present, but deciding where to take tissue samples has traditionally been difficult. MRI scans are changing that by helping doctors see suspicious ...

Prostate cancer is the second most common cancer in men worldwide. As clinical guidelines increasingly recommend MRI before ...

Using prostate MRI before a biopsy is a real advance in prostate cancer diagnosis. Multiple randomized trials have shown that ...

Although mpMRI can improve targeting of clinically significant prostate cancer, its performance depends in part on obtaining ...

Hyperpolarization approaches in magnetic resonance overcome sensitivity limitations imposed by thermal magnetization and are ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ...